· Cumulative activity as of the end of december 2015
thousands of euros
2014
2015
Variation at current exchange rates
Variation at constant exchange rates
France
343,891
361,765
+5.2%
+5.2%
Europe (excluding France)
198,918
167,714
-15.7%
-11.9%
North America
52,813
63,858
+20.9%
+3.8%
Other countries
14,126
14,466
+2.4%
+5.7%
Group total
609,748
607,803
-0.3%
-0.5%
thousands of euros
2014
2015
Variation at current exchange rates
Variation at constant exchange rates
Non-proprietary Homeopathic Medicines
305,501
310,555
+1.7%
+0.8%
OTC Specialties
303,549
296,954
-2.2%
-1.7%
Other
698
294
-57.9%
-37.7%
Group total
609,748
607,803
-0.3%
-0.5%
· Quarterly activity in 2015 ( variation at current rate)
thousands of euros
1st quarter
2nd quarter
3rd quarter
4th quarter
2014
2015
Var. 15/14
2014
2015
Var. 15/14
2014
2015
Var. 15/14
2014
2015
Var. 15/14
France
82,749
89,584
+8.3%
74,269
76,864
+3.5%
92,466
97,767
+5.7%
94,407
97,550
+3.3%
Europe (excluding France)
39,967
40,657
+1.7%
33,570
29,943
-10.8%
62,758
50,614
-19.4%
62,623
46,500
-25.7%
North America
12,662
17,193
+35.8%
10,625
12,894
+21.4%
13,109
16,055
+22.5%
16,417
17,716
+7.9%
Other countries
4,831
4,622
-4.3%
2,943
3,816
+29.7%
3,779
3,594
-4.9%
2,573
2,434
-5.4%
Group total
140,209
152,056
+8.4%
121,407
123,517
+1.7%
172,112
168,030
-2.4%
176,020
164,200
-6.7%
thousands of euros
1st quarter
2nd quarter
3rd quarter
4th quarter
2014
2015
Var. 15/14
2014
2015
Var. 15/14
2014
2015
Var. 15/14
2014
2015
Var. 15/14
Non-proprietary Homeopathic Medicines
77,919
79,191
+1.6%
73,072
74,354
+1.8%
72,957
73,677
+1.0%
81,553
83,333
+2.2%
OTC Specialties
62,196
72,880
+17.2%
48,058
49,030
+2.0%
99,025
94,328
-4.7%
94,270
80,716
-14.4%
Other
94
-15
-
277
133
-52.0%
130
25
-80.8%
197
151
-23.4%
Group total
140,209
152,056
+8.4%
121,407
123,517
+1.7%
172,112
168,030
-2.4%
176,020
164,200
-6.7%
Highlights of the fourth quarter
Sales revenue of the fourth quarter 2015 was down by 6.7% (-6.4% at constant rate). Such decrease mainly results from the situation in Russia.
Thus, the 2015 operating income will be lower than in 2014.
On December 22, 2015, our company has set up a new subsidiary in India and thus confirms its involvement in the development of homeopathy in the world.
Our next update: March 16, 2016, after the close of the stock market, publication of 2015 results.
Person responsible for financial information: Christian Boiron
Contact for financial information: Véronique Bouscayrol
Investor relations: +33 (0) 4.78.45.63.43 - e-mail : boironfinances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information is online at: www.boironfinance.com
Information réglementée Communiqués au titre de l′obligation d′information permanente :
- Communiqué sur comptes, résultats, chiffres d′affaires
Full and original press release in PDF:
http://www.actusnews.com/documents_communiques/ACTUS-0-42839-BOI-210116-CA-15-GB.pdf
Laboratoires BOIRON was founded in France almost a century ago, under the impetus of homeopathic doctors who wanted to benefit from the most reliable medicines possible. Homeopathic medicines have many advantages in that they can be prescribed and advised in first line whenever relevant, in both urban and hospital settings. All actions aim to contribute to major public health issues.
Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin.
There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties).
BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries.
Net sales are distributed geographically as follows: France (52.4%), Europe (22.5%), North America (22.6%) and other (2.5%).
BOIRON 
